Kali Therapeutics Named to the 2026 Endpoints 11, Recognizing Biotech's Most Promising Startups

Positive

AI Analysis

Summary

Kali Therapeutics, a clinical-stage biotech company developing immune-resetting and multi-specific therapies, was named to the 2026 Endpoints 11 list recognizing the most promising biotech startups.

Importance:3/10

Sentiment:

0.60

recognitionstartupclinical-stageimmune therapymulti-specific therapies

Related Companies

$GBIO

Read the original article

Published by PR Newswire Biotech on September 25, 2026 2:01 PM

Read Original